文献速递自身免疫性与大疱性皮肤病

网络Meta分析比较天疱疮一线保激素辅助治疗

Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus.
PubMed 文献 · J Am Acad Dermatol · 2020-08-13

该网络Meta分析纳入10项随机对照试验共592例天疱疮患者,比较7种一线保激素辅助剂。利妥昔单抗在诱导缓解上最优,优于单用激素(OR 14.35,95%CI 4.71-43.68),且利妥昔单抗、硫唑嘌呤和环磷酰胺冲击治疗均可降低累积糖皮质激素剂量。

要点

  • 利妥昔单抗诱导缓解优于单用激素,OR 14.35(95%CI 4.71-43.68)。
  • 利妥昔单抗降低累积激素剂量最多,平均差-11830.5 mg。
  • 硫唑嘌呤和环磷酰胺冲击也可减少累积激素剂量。

核心结论

  • 网络Meta分析显示利妥昔单抗是有效且耐受性好的保激素辅助剂。

研究设计与样本

  • 系统检索随机对照试验,纳入10项试验共592例天疱疮患者进行网络Meta分析。

主要发现

  • 利妥昔单抗诱导缓解优于单用激素,OR 14.35(95%CI 4.71-43.68)。
  • 利妥昔单抗降低累积激素剂量平均差-11830.5 mg(95%CI -14089.48至-9571.52)。
  • 硫唑嘌呤降低累积激素剂量平均差-3032.48 mg(95%CI -4700.74至-1364.22)。
  • 环磷酰胺冲击降低累积激素剂量平均差-2469.54 mg(95%CI -4128.42至-810.66)。

关键数值与推荐

  • 共评估7种保激素辅助剂,主要结局为缓解比例和平均累积激素剂量。

临床怎么用

  • 天疱疮一线治疗可优先考虑利妥昔单抗作为保激素辅助剂。
  • 硫唑嘌呤和环磷酰胺冲击可作为减少激素累积剂量的备选方案。

局限性

  • 结果主要由少量研究驱动,间接比较导致效应估计不精确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Steroid-sparing adjuvants may enhance oral glucocorticoid benefits in pemphigus treatment. Selecting the optimal therapeutic option among various first-line steroid-sparing adjuvants is often a clinical challenge due to the lack of head-to-head clinical trials. OBJECTIVE: To determine the best first-line steroid-sparing adjuvants for pemphigus treatment. METHODS: Randomized controlled trials comparing different steroid-sparing adjuvants in patients with pemphigus were identified through a systematic literature search and subjected to a network meta-analysis. The primary outcomes were the proportion of remission and the mean cumulative glucocorticoid dose. RESULTS: Ten trials involving 592 patients were analyzed. Among the 7 steroid-sparing adjuvants evaluated, rituximab was the most effective for achieving remission and was more effective than steroid alone (odds ratio, 14.35; 95% confidence interval [CI], 4.71-43.68). Rituximab, azathioprine, and cyclophosphamide pulse therapy enabled the reduction of the cumulative glucocorticoid doses compared to the use of steroid alone: mean differences, -11,830.5 mg (95% CI, -14,089.48 to -9571.52), -3032.48 mg (-4700.74 to -1364.22), and -2469.54 mg (-4128.42 to -810.66), respectively. LIMITATIONS: The results were driven primarily by a small number of studies, and the effect estimates are imprecise because of indirect comparisons. CONCLUSION: Network meta-analysis showed that rituximab appears to be an efficacious, well tolerated steroid-sparing adjuvant for pemphigus.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Lee MS, Yeh YC, Tu YK, et al. Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2020. PMID: 32798583. doi:10.1016/j.jaad.2020.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。